Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Current Leases (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Current Leases for 5 consecutive years, with $85210.0 as the latest value for Q3 2025.

  • On a quarterly basis, Current Leases fell 34.39% to $85210.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $85210.0, a 34.39% decrease, with the full-year FY2025 number at $116314.0, changed N/A from a year prior.
  • Current Leases was $85210.0 for Q3 2025 at Neuphoria Therapeutics, down from $116314.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $129881.0 in Q3 2024 to a low of $85210.0 in Q3 2025.
  • A 4-year average of $114445.5 and a median of $116314.0 in 2025 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: increased 0.19% in 2023, then plummeted 34.39% in 2025.
  • Neuphoria Therapeutics' Current Leases stood at $114631.6 in 2022, then increased by 0.19% to $114851.7 in 2023, then rose by 3.17% to $118492.0 in 2024, then fell by 28.09% to $85210.0 in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Current Leases are $85210.0 (Q3 2025), $116314.0 (Q2 2025), and $121738.0 (Q1 2025).